ARTS-011 (TYK2 allosteric inhibitor)
Provider 
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private

Highly selective TYK2 allosteric inhibitor for autoimmune disorders.
ARTS-011 is a highly selective, potent and orally available TYK2 allosteric inhibitor for inflammatory disorders like psoriasis and lupus. It shows excellent selectivity vs other JAK kinases and strong DMPK/safety profiles.
IND cleared by China CDE April 2023. Phase 1 completed in healthy volunteers in China. Targets autoimmune diseases.
Alumis

Envudeucitinib (ESK-001)
alumis.com
InnoCare Pharma

Fadeucravacitinib (ICP-488)
innocarepharma.com
Bristol Myers Squibb

Sotyktu (deucravacitinib)
bms.com
Takeda

Zasocitinib (TAK-279)
takeda.com
Adds products that compete with one of ARTS-011 (TYK2 allosteric inhibitor)’s direct competitors but not with ARTS-011 (TYK2 allosteric inhibitor) itself. They are shaded, and Linked Through names the direct competitor each one competes with.
| Attribute | ARTS-011 (TYK2 allosteric inhibitor) | Envudeucitinib (ESK-001) | Fadeucravacitinib (ICP-488) | Sotyktu (deucravacitinib) | Zasocitinib (TAK-279) | |
|---|---|---|---|---|---|---|
| Provider | ||||||
| Founded | 2020 | 2021 | 2015 | 1887 | 1781 | |
| Sells To | Enterprise | Enterprise | — | Consumers, Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Recurring, Software | — | Recurring, Software | — | |
| Ownership | Private | Venture-backed | — | Public | Venture-backed |
Provider 
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Provider 
Founded 2021
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
Provider 
Founded 2015
Sells To —
Pricing Model —
Ownership —
Provider 
Founded 1887
Sells To Consumers, Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 1781
Sells To Enterprise
Pricing Model —
Ownership Venture-backed


Otezla (apremilast) is Amgen's oral phosphodiesterase 4 inhibitor for plaque psoriasis and psoriatic arthritis.
Otezla (apremilast) is Amgen's oral phosphodiesterase 4 inhibitor for plaque psoriasis and psoriatic arthritis.
